Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
blood diseases
Pharma
AZ's Ultomiris hits goal in ph. 3 IgAN trial
AstraZeneca's Ultomiris has delivered in a phase 3 trial in IgAN, setting up the C5 inhibitor for potential approval in a 5th indication.
Kevin Dunleavy
Apr 21, 2026 10:35am
FDA probes safety of Takeda's Adzynma after reported death
Nov 21, 2025 11:40am
Sanofi's Wayrilz snags FDA endorsement in ITP
Aug 29, 2025 5:59pm
AZ touts Ultomiris results in post-transplant complication trial
Jun 16, 2025 10:32am
As Pfizer bows out, CSL keeps hemophilia gene therapy hopes alive
Apr 11, 2025 10:32am
Sanofi sells rare disease med Enjaymo to Recordati for $825M
Oct 4, 2024 10:11am
